UY38797A - Anticuerpos inmunomoduladores y métodos de uso de los mismos - Google Patents

Anticuerpos inmunomoduladores y métodos de uso de los mismos

Info

Publication number
UY38797A
UY38797A UY0001038797A UY38797A UY38797A UY 38797 A UY38797 A UY 38797A UY 0001038797 A UY0001038797 A UY 0001038797A UY 38797 A UY38797 A UY 38797A UY 38797 A UY38797 A UY 38797A
Authority
UY
Uruguay
Prior art keywords
methods
antibodies
immunomodulating antibodies
immunomodulating
disclosed
Prior art date
Application number
UY0001038797A
Other languages
English (en)
Spanish (es)
Inventor
D Puri Kamal
Siddarth Chandrasekaran
L Conerly Melissa
M Simmons Randi
T Smith Tyrel
E Branum Mark
Peter Probst
Original Assignee
Oncoresponse Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoresponse Inc filed Critical Oncoresponse Inc
Publication of UY38797A publication Critical patent/UY38797A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
UY0001038797A 2019-07-19 2020-07-20 Anticuerpos inmunomoduladores y métodos de uso de los mismos UY38797A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962876579P 2019-07-19 2019-07-19
US201962876580P 2019-07-19 2019-07-19
US201962878265P 2019-07-24 2019-07-24

Publications (1)

Publication Number Publication Date
UY38797A true UY38797A (es) 2021-01-29

Family

ID=74193810

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038797A UY38797A (es) 2019-07-19 2020-07-20 Anticuerpos inmunomoduladores y métodos de uso de los mismos

Country Status (14)

Country Link
US (6) US11634501B2 (cg-RX-API-DMAC7.html)
EP (1) EP4004051A4 (cg-RX-API-DMAC7.html)
JP (2) JP7852904B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220035452A (cg-RX-API-DMAC7.html)
CN (1) CN114423787B (cg-RX-API-DMAC7.html)
AU (1) AU2020315878A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000876A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147103A1 (cg-RX-API-DMAC7.html)
IL (1) IL289829A (cg-RX-API-DMAC7.html)
MX (1) MX2022000726A (cg-RX-API-DMAC7.html)
PH (1) PH12022550141A1 (cg-RX-API-DMAC7.html)
TW (1) TW202116809A (cg-RX-API-DMAC7.html)
UY (1) UY38797A (cg-RX-API-DMAC7.html)
WO (1) WO2021016128A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
US20240084029A1 (en) * 2021-01-20 2024-03-14 Oncoresponse, Inc. Use of immunomodulatory antibodies to treat fibrotic diseases
MX2023008485A (es) * 2021-01-20 2023-07-28 Oncoresponse Inc Anticuerpos inmunomoduladores y usos de estos.
US11845791B2 (en) * 2021-03-08 2023-12-19 Medimmune, Llc Antibodies directed against GDF-15
WO2023034762A2 (en) * 2021-08-30 2023-03-09 Obi Pharma, Inc. Bispecific dendritic cell engager and uses thereof
WO2023034963A2 (en) * 2021-09-03 2023-03-09 Oncoresponse, Inc. Combinations of immunotherapies and uses thereof
AU2022426854A1 (en) * 2021-12-31 2024-06-13 The Trustees Of Columbia University In The City Of New York Bispecific molecules to target the first cell
EP4615480A1 (en) * 2022-11-07 2025-09-17 Alector LLC Uses of siglec-9 ecd fusion molecules in cancer treatment
JP2026519901A (ja) * 2023-01-27 2026-06-19 ヴィーアイビー ヴィーゼットヴィー Cd163結合複合体
AU2024391672A1 (en) 2023-11-30 2026-05-21 Oncospear Aps Anti-cd163 antibodies with improved adcc capabilities

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE60140069D1 (de) 2000-10-16 2009-11-12 Cytoguide Aps Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür
AU2003243058A1 (en) 2002-05-27 2003-12-12 Bioceros B.V. Methods for using the cd163 pathway for modulating an immune response
EP1367393A1 (en) * 2002-05-27 2003-12-03 MacroZyme B.V. Methods for using the CD 163 pathway for modulating an immune response
AU2004204462B2 (en) 2003-01-09 2012-03-08 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8053569B2 (en) 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
EP2632955A1 (en) * 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
KR102119840B1 (ko) 2011-07-11 2020-06-09 아이크노스 사이언스 에스. 아. Ox40에 결합하는 항체 및 이들의 용도
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
AU2014213009B2 (en) 2013-02-01 2019-01-03 Kira Biotech Pty Limited Anti-CD83 antibodies and use thereof
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗angptl8抗體及其用途
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR101787485B1 (ko) 2015-12-30 2017-11-15 재단법인 의약바이오컨버젼스연구단 재조합 picp 단백질 및 이에 특이적으로 결합하는 항체의 제조방법
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
EP3491387A1 (en) 2016-07-28 2019-06-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods of treatement of cancer disease by targetting tumor associated macrophage
WO2018090144A1 (en) 2016-11-17 2018-05-24 Innovative Targeting Solutions Inc. Chimeric receptors, biosensor host cells and methods/uses thereof
CN110036029A (zh) 2016-11-17 2019-07-19 瑞泽恩制药公司 用抗angptl8抗体处理肥胖的方法
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
CN112424358B (zh) 2018-06-26 2025-07-01 协和麒麟株式会社 与细胞粘附分子3结合的抗体
WO2020018434A1 (en) 2018-07-17 2020-01-23 Scripps Health Compositions and methods for disrupting a macrophage network
WO2020058372A1 (en) 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
US11634501B2 (en) 2019-07-19 2023-04-25 Oncoresponse, Inc. Immunomodulatory antibodies and methods of use thereof
WO2023034963A2 (en) 2021-09-03 2023-03-09 Oncoresponse, Inc. Combinations of immunotherapies and uses thereof

Also Published As

Publication number Publication date
CA3147103A1 (en) 2021-01-28
EP4004051A4 (en) 2023-08-23
US11034770B2 (en) 2021-06-15
US11827715B2 (en) 2023-11-28
JP2026026087A (ja) 2026-02-16
US20220289861A1 (en) 2022-09-15
CN114423787B (zh) 2025-01-24
JP2022540806A (ja) 2022-09-20
US20210253733A1 (en) 2021-08-19
MX2022000726A (es) 2022-02-10
TW202116809A (zh) 2021-05-01
US20260103535A1 (en) 2026-04-16
KR20220035452A (ko) 2022-03-22
US20210047424A1 (en) 2021-02-18
PH12022550141A1 (en) 2023-12-04
EP4004051A1 (en) 2022-06-01
IL289829A (en) 2022-03-01
BR112022000876A2 (pt) 2022-04-26
US11634501B2 (en) 2023-04-25
JP7852904B2 (ja) 2026-04-28
AU2020315878A1 (en) 2022-03-03
WO2021016128A1 (en) 2021-01-28
US20240101696A1 (en) 2024-03-28
US20240239914A1 (en) 2024-07-18
CN114423787A (zh) 2022-04-29
US12195549B2 (en) 2025-01-14

Similar Documents

Publication Publication Date Title
MX2022000726A (es) Anticuerpos inmunomoduladores y metodos de uso de los mismos.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2020001983A2 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anticd39
CL2023002048A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos
MX2016009428A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
MX2016011619A (es) Anticuerpos anti-egfrviii y usos de los mismos.
MX2019001845A (es) Arquitectura de indexado que incluye una disposicion de abanico.
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
BR112015030972A8 (pt) células sc-beta e composições e métodos para geração das mesmas
CL2018002140A1 (es) Métodos y composiciones para aumentar la eficiencia de modificación genética dirigida usando reparación genética mediada por oligonucleótidos
BR112017008914A2 (pt) método para tratar câncer, composição e uso da composição
MX388517B (es) Polipéptidos de transposasa y sus usos.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2015015221A (es) Nanoportadores sintéticos tolerogénicos y macromoléculas terapéuticas para efectos farmacodinámicos reducidos o intensificados.
MA51107A (fr) Cellules souches et progénitrices hématopoïétiques humaines cd34+ modifiées par crispr-cas9 et utilisations associées
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
BR112022000120A2 (pt) Projeto e sínteses eficientes de conjugados de lipídeo-fluoresceína para terapia de células car-t
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX2017007033A (es) Aparato de absorcion de energia.
MX383944B (es) Composiciones para el cuidado personal.
MX2016013686A (es) Anticuerpos de antigeno anti-tf humanizado.
CL2022003684A1 (es) Agentes de unión a lair-1 y métodos para su uso
MX2016012823A (es) Inserto vaginal.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20241206